Opinion

Video

Emerging Treatments for Myelofibrosis

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Related Content
Five Under 5: Top Oncology Videos for the Week of 4/13
April 20th 2025

Five Under 5: Top Oncology Videos for the Week of 4/13

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Ann S. LaCasce, MD, MMSc, associate professor, medicine, lymphoma specialist, Dana-Farber Cancer Institute, Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
March 26th 2025

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

Juan Carlos Hernández-Boluda, MD, PhD, an associated physician in the Hematology and Medical Oncology Service at Hospital Clínico of Valencia, Spain
April 18th 2025

An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Bexmarilimab Plus Azacitidine in R/R Higher-Risk MDS | Image credit: © Maris – stock.adobe.com
April 15th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

DLBCL | Image Credit: © LASZLO – stock.adobe.com
April 14th 2025

Glofitamab Plus Chemo Wins European Approval for R/R DLBCL